KYMRKymera Therapeutics, Inc.
$112.32+129% 1Y
$112.32
$50.8752 weeks$127.24
Is the price fair?
What KYMR's price assumes
Kymera Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 244× revenue.
244
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 6.06
Price / book · today's price, fiscal year to Dec 31, 2025
- EV / sales
- 223
EV / sales
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 6.06
- EV / EBIToperating margin −334%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 223
- Market capitalisation
- $9.58B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
On our screens:Most shorted stocks